MedTrace Logo

Pilot Study for HLA Identical Living Donor Renal Transplant Recipients

NCT00352092 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-11-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of a steroid-free and calcineurin-inhibitor free treatment regimen for patients who are receiving a kidney transplant from a living donor that is HLA-identical (has a similar immune system).

Conditions

  • Renal Transplant

Interventions

DRUG

calcineurin inhibitor

DRUG

sirolimus

DRUG

mycophenolate mofetil

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Rita Alloway, Pharm.D. · University of Cincinnati

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00352092 on ClinicalTrials.gov